Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer

BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. METHODS:...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Han, Sae-Won, Cha, Yongjun, Paquet, Agnes, Huang, Weidong, Weidler, Jodi, Lie, Yolanda, Sherwood, Thomas, Bates, Michael, Haddad, Mojgan, Park, In Hae, Oh, Do-Youn, Lee, Keun Seok, Im, Seock-Ah, Bang, Yung-Jue, Ro, Jungsil, Kim, Tae-You
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2012
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3407213/
https://ncbi.nlm.nih.gov/pubmed/22848366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0039943
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים